Gritstone Oncology

Gritstone Oncology

Gritstone Oncology is a Emeryville, California-based biotechnology company developing neoantigen-specific cancer immunotherapies.

Gritstone Oncology is a biotechnology company that specializes in developing cancer immunotherapies. It was established in 2015 by Andrew Allen and Mark Cobbold. The company is headquartered in Emeryville, California, United States. It also maintains operations in Cambridge, Massachusetts and Pleasanton, California. Gritstone Oncology has been a publicly-listed company since 2018 and previously received funding from investors such as Redmile Group, Lilly Asia Ventures, and GV.

Product & Service

Gritstone Oncology develops personalized cancer immunotherapies, based on identifying tumor-specific neoantigens in cancer patients. The company developed an artificial intelligence called Gristone EDGE, dedicated to discovering specific neoantigens based on certain tumor mutations as derived from a previously existing database, and matching these neoantigens to the appropriate immunotherapy. Gritstone Oncology expects that through the use of these methods, the company can administer the right immunotherapy to boost the patient's immune system, with the goal of eradicating the tumor.

The company offers two types of products based on this approach The first one is a more personalized approach tailored for the patient based on their cancer diagnosis and immune system, while the second, called SLATE, utilizes previously proven immunotherapies on patients exhibiting similar types of tumor neoantigens.

Timeline

Funding rounds

Funding round
Funding type
Funding round amount (USD)
Funding round date
Investment
Gritstone Oncology funding round, September 2017
92,700,000
September 2017
1 Result
Results per page:
Page 1 of 1

People

Name
Role
LinkedIn

Further reading

Title
Author
Link
Type
Date

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

News

Title
Author
Date
Publisher
Description
Allison DeAngelis
February 16, 2021
Business Insider
Coronaviruses will remain part of our lives forever. Drug companies are exploring ways to address COVID-19 and similar viruses.
Ben Adams
February 1, 2021
FierceBiotech
Initially known as a machine learning biotech focused on cancer, Gritstone Oncology has been broadening its scope to include a very early look at treatments for COVID-19 and, now, another infectious disease.
Amirah Al Idrus
January 19, 2021
FierceBiotech
Gritstone Oncology, the biotech working on cancer vaccines based on traditional infectious disease immunology, is bringing that approach back to its roots. It's working on a vaccine against SARS-CoV-2, the virus that causes COVID-19, that could also work against other viruses in this family in the case of a future pandemic.
BioSpace
June 10, 2020
BioSpace
Gritstone Oncology, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer immunotherapies to fight multiple cancer types, today announced that Jean-Charles Soria, M.D., Ph.D., chief executive officer of Gustave Roussy Cancer Center, has joined the company's scientific advisory board (SAB). "We are delighted that our co-founder Jean-Charles, a world-class medical oncologist and scientist, has r

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.